146 related articles for article (PubMed ID: 2297574)
1. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption.
Ishikawa H; Tanaka H; Iwato K; Tanabe O; Asaoku H; Nobuyoshi M; Yamamoto I; Kawano M; Kuramoto A
Blood; 1990 Feb; 75(3):715-20. PubMed ID: 2297574
[TBL] [Abstract][Full Text] [Related]
2. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
[TBL] [Abstract][Full Text] [Related]
3. Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD
Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma.
Kawano M; Yamamoto I; Iwato K; Tanaka H; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Ohmoto Y; Hirai Y
Blood; 1989 May; 73(6):1646-9. PubMed ID: 2785413
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
[TBL] [Abstract][Full Text] [Related]
6. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.
Josse RG; Murray TM; Mundy GR; Jez D; Heersche JN
J Clin Invest; 1981 May; 67(5):1472-81. PubMed ID: 6262378
[TBL] [Abstract][Full Text] [Related]
7. Production of interleukin-1 by bone marrow myeloma cells.
Cozzolino F; Torcia M; Aldinucci D; Rubartelli A; Miliani A; Shaw AR; Lansdorp PM; Di Guglielmo R
Blood; 1989 Jul; 74(1):380-7. PubMed ID: 2665838
[TBL] [Abstract][Full Text] [Related]
8. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
Bataille R; Chappard D; Klein B
Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
[TBL] [Abstract][Full Text] [Related]
9. Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss.
Kim CH; Cheng SL; Kim GS
J Endocrinol; 1999 Sep; 162(3):371-9. PubMed ID: 10467228
[TBL] [Abstract][Full Text] [Related]
10. Development of an in vivo model of human multiple myeloma bone disease.
Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
[TBL] [Abstract][Full Text] [Related]
11. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
Lee JW; Chung HY; Ehrlich LA; Jelinek DF; Callander NS; Roodman GD; Choi SJ
Blood; 2004 Mar; 103(6):2308-15. PubMed ID: 14615378
[TBL] [Abstract][Full Text] [Related]
12. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
[TBL] [Abstract][Full Text] [Related]
14. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites.
Chen YH; Desai P; Shiao RT; Lavelle D; Haleem A; Chen J
Blood; 1996 Jan; 87(1):314-23. PubMed ID: 8547658
[TBL] [Abstract][Full Text] [Related]
16. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
Durie BG; Salmon SE; Mundy GR
Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma.
Kawano M; Tanaka H; Ishikawa H; Nobuyoshi M; Iwato K; Asaoku H; Tanabe O; Kuramoto A
Blood; 1989 Jun; 73(8):2145-8. PubMed ID: 2786435
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism.
Linkhart TA; MacCharles DC
Endocrinology; 1992 Nov; 131(5):2297-305. PubMed ID: 1425428
[TBL] [Abstract][Full Text] [Related]
19. Effect of interleukin-1 and dexamethasone on interleukin-6 production and growth in human meningiomas.
Jones TH; Justice SK; Timperley WR; Royds JA
J Pathol; 1997 Dec; 183(4):460-8. PubMed ID: 9496264
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of bone lesions in multiple myeloma and lymphoma.
Roodman GD
Cancer; 1997 Oct; 80(8 Suppl):1557-63. PubMed ID: 9362422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
